Cencora, Inc. $COR Shares Sold by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC cut its position in Cencora, Inc. (NYSE:COR) by 7.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 81,395 shares of the company’s stock after selling 7,014 shares during the period. Wedge Capital Management L L P NC’s holdings in Cencora were worth $27,491,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of COR. Norges Bank acquired a new position in shares of Cencora during the second quarter worth $695,215,000. Marshall Wace LLP lifted its holdings in Cencora by 518.9% during the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after buying an additional 1,672,762 shares during the last quarter. Mizuho Markets Americas LLC lifted its holdings in Cencora by 116.4% during the 3rd quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company’s stock worth $66,506,000 after buying an additional 1,511,906 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Cencora by 528.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock worth $461,250,000 after acquiring an additional 1,241,186 shares in the last quarter. Finally, Viking Global Investors LP boosted its position in shares of Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after acquiring an additional 1,013,913 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the transaction, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at $23,669,713.98. The trade was a 7.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.38% of the company’s stock.

Cencora Stock Down 1.8%

Cencora stock opened at $312.28 on Friday. Cencora, Inc. has a fifty-two week low of $267.40 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The company has a market capitalization of $60.75 billion, a P/E ratio of 37.53, a PEG ratio of 1.48 and a beta of 0.68. The stock has a 50-day simple moving average of $352.05 and a 200-day simple moving average of $340.52.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. The firm had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the business posted $3.73 EPS. Equities research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were given a dividend of $0.60 per share. The ex-dividend date was Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. Cencora’s dividend payout ratio (DPR) is 28.85%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on COR. Barclays raised their target price on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research report on Friday, February 13th. Wall Street Zen downgraded Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. JPMorgan Chase & Co. increased their price target on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Weiss Ratings raised shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a report on Thursday, February 5th. Finally, Wells Fargo & Company boosted their price objective on shares of Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Twelve research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $403.17.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.